Published in Mol Med on September 01, 1996
PAI-1 in tissue fibrosis. J Cell Physiol (2012) 2.26
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem (2008) 1.55
A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol (2001) 1.51
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther (2010) 1.46
Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A (1998) 1.44
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest (2001) 1.41
Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. Am J Pathol (2003) 1.25
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A (1999) 1.23
Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol (2011) 1.06
Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A (2002) 1.04
Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity (Silver Spring) (2011) 1.02
Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. PPAR Res (2009) 1.01
Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem Biophys Res Commun (2010) 0.86
Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1. Mol Endocrinol (2009) 0.85
Mechanisms of thrombosis in obesity. Curr Opin Hematol (2013) 0.84
Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue. Oxid Med Cell Longev (2013) 0.84
Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients? Cerebrovasc Dis (2008) 0.76
Plasminogen activator inhibitor-1 does not contribute to the pulmonary pathology induced by acute exposure to ozone. Physiol Rep (2016) 0.75
Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease. PPAR Res (2011) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest (1973) 31.28
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. J Biol Chem (1964) 21.04
Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A (1989) 15.69
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care (1991) 9.95
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell (1975) 8.29
Pathophysiology of insulin resistance in human disease. Physiol Rev (1995) 3.95
Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism (1977) 1.93
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem (1989) 1.92
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest (1996) 1.65
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes (1994) 1.50
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res (1984) 1.46
Abdominal fat distribution and disease: an overview of epidemiological data. Ann Med (1992) 1.42
Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost (1989) 1.38
Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood (1988) 1.34
A simple, non-chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. J Immunol Methods (1987) 1.31
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism (1986) 1.30
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Obesity, fat distribution and cardiovascular disease. Int J Obes (1991) 1.16
Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J Lab Clin Med (1985) 1.09
Construction of recombinant RNA templates for use as internal standards in quantitative RT-PCR. Biotechniques (1993) 1.05
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism (1993) 1.02
Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation (1995) 1.01
Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost (1988) 0.98
Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis (1989) 0.98
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A (1991) 0.97
Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia (1993) 0.96
Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost (1992) 0.94
Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost (1989) 0.94
Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost (1992) 0.93
Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism (1989) 0.93
Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med (1993) 0.86
Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res (1993) 0.85
Cellular and molecular biology in the study of the physiopathology of obesity. Acta Clin Belg Suppl (1992) 0.84
The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost (1991) 0.83
Hypofibrinolysis and insulin-resistance. Diabete Metab (1991) 0.83
Anatomy and physiology of adipose tissue. Clin Plast Surg (1989) 0.83
Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb (1994) 0.82
Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci (Lond) (1990) 0.80
Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol (1993) 0.80
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem (1994) 6.31
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A (1977) 2.83
Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem (1991) 2.52
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem (1985) 2.23
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A (1983) 2.20
Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem (1988) 2.04
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem (1989) 1.92
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest (1986) 1.89
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1986) 1.85
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol (1982) 1.77
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest (1996) 1.65
Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A (1988) 1.64
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest (1995) 1.52
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest (1984) 1.50
Type 1 plasminogen activator inhibitor. Prog Hemost Thromb (1989) 1.49
Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med (1995) 1.46
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A (1985) 1.46
Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol (1993) 1.45
Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A (1998) 1.44
Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest (2001) 1.41
Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation (2001) 1.39
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood (1998) 1.29
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost (2006) 1.28
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. J Clin Invest (1992) 1.26
The fibrinolytic system of the vascular wall. Clin Haematol (1985) 1.25
Tissue distribution of factor VIII gene expression in vivo--a closer look. Thromb Haemost (2001) 1.24
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol (2001) 1.23
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A (1999) 1.23
Comparative studies of the fibrinolytic activity of cultured vascular cells. Thromb Res (1979) 1.22
Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem (1991) 1.21
Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest (1998) 1.20
Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood (1987) 1.20
Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem (1989) 1.20
Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. J Clin Invest (1979) 1.20
Tissue factor expression during human and mouse development. Am J Pathol (1996) 1.19
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem (1994) 1.18
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood (1986) 1.15
Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci (1989) 1.12
Replication of dengue and junin viruses in cultured rabbit and human endothelial cells. Infect Immun (1978) 1.12
Gene expression during the development of Bacillus subtilis bacteriophage phi29. II. Resolution of viral-specific ribonucleic acid molecules. J Virol (1973) 1.12
Serum-mediated suppression of cell-associated plasminogen activator activity in cultured endothelial cells. Cell (1980) 1.11
Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J Lab Clin Med (1985) 1.09
Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci U S A (1991) 1.09
Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med (2000) 1.08
Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys (1988) 1.08
Effects of acidified fetal bovine serum on the fibrinolytic activity and growth of cells in culture. J Cell Physiol (1978) 1.06
Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation (1994) 1.04
Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J Clin Invest (1993) 1.04
Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry (1986) 1.04
SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. J Biol Chem (1991) 1.02
An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem (1981) 1.01
Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem (1989) 1.01
Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest (1995) 1.00
Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. Biochim Biophys Acta (1991) 1.00
Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology (1985) 0.99
Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol (1997) 0.99
Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J (2001) 0.99
Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis (1988) 0.99
The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol (1990) 0.98
Characterization of two monoclonal antibodies against human tissue-type plasminogen activator. Thromb Haemost (1985) 0.96
Distribution of vitronectin mRNA during murine development. Dev Dyn (1995) 0.95
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood (1994) 0.94
Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol (1993) 0.93
Messenger RNA for plasminogen activator inhibitor. Thromb Res (1986) 0.92
The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells. Thromb Haemost (1986) 0.92
Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost (1998) 0.91
Endotoxin stimulates expression of the murine urokinase receptor gene in vivo. Am J Pathol (1995) 0.91
Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev (1990) 0.91
Role of tumor necrosis factor alpha in induction of murine CD14 gene expression by lipopolysaccharide. Infect Immun (1997) 0.91
Regulation of tissue factor gene expression in obesity. Blood (2001) 0.90
Intracellular plasminogen activator activity in growing and quiescent cells. J Cell Physiol (1978) 0.89
Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol (1990) 0.89
The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol (1997) 0.89
Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood (1989) 0.89
The leptin receptor system of human platelets. J Thromb Haemost (2005) 0.88
Expression of transforming growth factor-beta and tumor necrosis factor-alpha in the plasma and tissues of mice with lupus nephritis. Lab Invest (2000) 0.88
Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo. J Biol Chem (1996) 0.87
Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol (1997) 0.87
Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. Blood (1983) 0.87
Protein C inhibitor is expressed in tubular cells of human kidney. J Clin Invest (1994) 0.86
Fibrinolytic pathways and the endothelium. Semin Thromb Hemost (1987) 0.86
Extrahepatic expression and regulation of protein C in the mouse. Am J Pathol (1998) 0.86
Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. Blood (1991) 0.85
The PAI-1/vitronectin interaction: two cats in a bag? Thromb Haemost (1995) 0.85